Georgia Expands Medical Cannabis Access
Georgia Governor Brian Kemp has signed Senate Bill 220 (SB 220), known as the “Putting Georgia’s Patients First Act,” which expands medical cannabis access in the state. The legislation, approved by Gov. Kemp on Tuesday, introduces new qualifying conditions, permits additional consumption methods, and modifies the state’s THC potency regulations for registered patients.
Under the provisions of SB 220, patients diagnosed with lupus will now be eligible to legally access medical cannabis. This builds upon existing state law that provides access for individuals with conditions such as cancer, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, ALS, autism spectrum disorder, and intractable pain. The bill, sponsored by Senator Matt Brass, also removes the requirement for many qualifying conditions that a patient’s status be classified as severe or end-stage to enter the medical cannabis program, broadening the patient base.
Revised Delivery Methods and Potency Regulations
The new law also expands the permissible methods for medical cannabis consumption. Previously, patients were limited to oils, tinctures, capsules, lozenges, topicals, and transdermal patches. SB 220 now permits vaping as a delivery method for patients aged 21 and older, while maintaining the prohibition on smoking for all patients.
Furthermore, the legislation revises the state’s THC potency limits. It replaces the previous 5 percent THC potency cap for medical cannabis products with a new limit of 12,000 milligrams of THC that a patient can possess at any single time. This adjustment shifts the regulatory focus from product concentration to total quantity held by the patient.
Regulatory Oversight and Public Awareness Initiatives
The Georgia Access to Medical Cannabis Commission, the body responsible for overseeing the state’s program, will assume new responsibilities under SB 220. These duties include conducting public awareness activities focused on the effective uses of medical cannabis and related products. This mandate extends to publishing materials and initiating outreach and public education efforts to inform the public, law enforcement, and healthcare providers about the state’s medical cannabis program and its potential benefits for eligible patients.
In a signing statement, Governor Kemp acknowledged the significance of these changes for affected patients while noting that they do not fundamentally alter Georgia’s position on the national landscape regarding cannabis policy. He stated, “This bill passed with a constitutional majority in both chambers of the General Assembly.” Governor Kemp also reiterated his reservations about recreational cannabis legalization, distinguishing it from the medical cannabis program, and affirmed that the bill does not address recreational use.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
